RJH Biosciences develops transfection reagents and nucleic acid delivery systems for various human cells, cell lines, and preclinical animal models. The company serves the biomedical research and development sector by providing tailored products and contract research services for applications such as mRNA, DNA, siRNA, and CRISPR delivery.
Subscribe to see JL Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
JL Biosciences, Inc. is a biotechnology company headquartered in La Grange, United States. Its most recent funding round raised $60,000 in April 2020. Xcout tracks 3 named people at JL Biosciences, Inc., including Hasan Uludag (Founder).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $60,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of JL Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
GenScript Biotech Corporation was founded in New Jersey in 2002 and accelerates innovation in biotechnology and healthcare. The company provides custom services and products to help researchers and corporate clients advance scientific discovery.
Emerald Health Bioceuticals Inc. develops biology-based life science solutions focused on enhancing human, animal, and plant life. The company utilizes advanced research, fermentation, biomanufacturing, and process development to create safe and sustainable products for its partners and customers.
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Bit Bio is a UK biotechnology company that develops technologies for precisely programming human cells, including its opti-ox platform for producing consistent, scalable cell types. It serves biomedical researchers, drug developers, and regenerative-medicine and cell-therapy developers with engineered human cells and related tools.
Glycogene Inc. is an RNA raw material supply and product development company headquartered in Biolake, Wuhan Optics Valley, China. Founded in 2019 by experts in nucleic acids, glycoscience, and enzyme evolution, the company also operates research and development and commercial manufacturing facilities in Shenzhen and Qingdao.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about JL Biosciences, Inc.? Suggest a correction · Work at JL Biosciences, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.